<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330134</url>
  </required_header>
  <id_info>
    <org_study_id>10-621A</org_study_id>
    <nct_id>NCT01330134</nct_id>
  </id_info>
  <brief_title>Comparison of Two Lidocaine Administration Techniques</brief_title>
  <official_title>Comparison of Two Lidocaine Administration Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of our study is to determine if technique of lidocaine administration can
      decrease pain perception.

      Hypothesis: There will be a significant difference in pain perception between patients who
      are given lidocaine on the skin surface prior to subcutaneous injection and patients who are
      given only subcutaneous injection by standard approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center prospective, randomized, blinded study assessing pain perception
      following 2 different lidocaine administration techniques in subjects who have planned
      medical procedures requiring local injection of lidocaine. Subjects will be approached and
      consented to participate in the study. They will be interviewed after the scheduled medical
      procedure to assess their pain using validated pain scores. An investigator who is not
      present for the procedure and blinded to the randomization will gather data regarding
      perceptions of pain from the entire procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Assessment: Overall</measure>
    <time_frame>post procedure (day 1)</time_frame>
    <description>Visual analog scale (VAS). This is a standardized analog scale with scores from 0-100. It measures level of pain with 0 meaning no pain and 100 meaning the most extreme level of pain. Higher values refer to a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Assessment: Lidocaine Injection</measure>
    <time_frame>post procedure (day 1)</time_frame>
    <description>visual analog scale (VAS) 0= no pain to 100 = worse pain possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Assessment: During Procedure</measure>
    <time_frame>post procedure (day 1)</time_frame>
    <description>visual analog scale (VAS) 0 = no pain to 100 = worse pain possible Rather, this is a pain assessment during the actual procedure rather than during the pre-procedure lidocaine injection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">481</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>lidocaine onto skin prior to lidocaine subcutaneous injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-2ml of 1% lidocaine dripped onto the surface of the skin immediately prior to subcutaneous injection of 1% lidocaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lidocaine subcutaneous injection alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1% lidocaine subcutaneous injection alone by standard approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine</intervention_name>
    <description>2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection</description>
    <arm_group_label>lidocaine onto skin prior to lidocaine subcutaneous injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine</intervention_name>
    <description>1% lidocaine subcutaneous injection alone</description>
    <arm_group_label>lidocaine subcutaneous injection alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients refered to the University of Chicago Medical Centers Procedure Service
             for a planned medical procedure requiring local injection of lidocaine.

        Exclusion Criteria:

          -  Patient who lack decisional capacity to consent

          -  Patients who lack the ability to answer questions in english using pain scales
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Kress, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <results_first_submitted>September 11, 2017</results_first_submitted>
  <results_first_submitted_qc>May 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2018</results_first_posted>
  <last_update_submitted>June 27, 2018</last_update_submitted>
  <last_update_submitted_qc>June 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>procedural</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lidocaine Onto Skin Prior to Lidocaine Subcutaneous Injection</title>
          <description>lidocaine: 2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection.</description>
        </group>
        <group group_id="P2">
          <title>Lidocaine Subcutaneous Injection Alone</title>
          <description>lidocaine: 1% lidocaine subcutaneous injection alone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine Onto Skin Prior to Lidocaine Subcutaneous Injection</title>
          <description>lidocaine: 2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection.</description>
        </group>
        <group group_id="B2">
          <title>Lidocaine Subcutaneous Injection Alone</title>
          <description>lidocaine: 1% lidocaine subcutaneous injection alone.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="244"/>
            <count group_id="B2" value="237"/>
            <count group_id="B3" value="481"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.5" lower_limit="46.4" upper_limit="68.6"/>
                    <measurement group_id="B2" value="56.8" lower_limit="44.8" upper_limit="65.4"/>
                    <measurement group_id="B3" value="57.4" lower_limit="45.2" upper_limit="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>white, nonhispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>white, hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>african american</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Assessment: Overall</title>
        <description>Visual analog scale (VAS). This is a standardized analog scale with scores from 0-100. It measures level of pain with 0 meaning no pain and 100 meaning the most extreme level of pain. Higher values refer to a worse outcome.</description>
        <time_frame>post procedure (day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Onto Skin Prior to Lidocaine Subcutaneous Injection</title>
            <description>lidocaine: 2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Subcutaneous Injection Alone</title>
            <description>lidocaine: 1% lidocaine subcutaneous injection alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Assessment: Overall</title>
          <description>Visual analog scale (VAS). This is a standardized analog scale with scores from 0-100. It measures level of pain with 0 meaning no pain and 100 meaning the most extreme level of pain. Higher values refer to a worse outcome.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="19.3"/>
                    <measurement group_id="O2" value="19.0" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Assessment: Lidocaine Injection</title>
        <description>visual analog scale (VAS) 0= no pain to 100 = worse pain possible</description>
        <time_frame>post procedure (day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Onto Skin Prior to Lidocaine Subcutaneous Injection</title>
            <description>lidocaine: 2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Subcutaneous Injection Alone</title>
            <description>lidocaine: 1% lidocaine subcutaneous injection alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Assessment: Lidocaine Injection</title>
          <description>visual analog scale (VAS) 0= no pain to 100 = worse pain possible</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="21.2"/>
                    <measurement group_id="O2" value="20.8" spread="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Assessment: During Procedure</title>
        <description>visual analog scale (VAS) 0 = no pain to 100 = worse pain possible Rather, this is a pain assessment during the actual procedure rather than during the pre-procedure lidocaine injection.</description>
        <time_frame>post procedure (day 1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine Onto Skin Prior to Lidocaine Subcutaneous Injection</title>
            <description>lidocaine: 2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Subcutaneous Injection Alone</title>
            <description>lidocaine: 1% lidocaine subcutaneous injection alone.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Assessment: During Procedure</title>
          <description>visual analog scale (VAS) 0 = no pain to 100 = worse pain possible Rather, this is a pain assessment during the actual procedure rather than during the pre-procedure lidocaine injection.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="19.4"/>
                    <measurement group_id="O2" value="16.6" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine Onto Skin Prior to Lidocaine Subcutaneous Injection</title>
          <description>lidocaine: 2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection</description>
        </group>
        <group group_id="E2">
          <title>Lidocaine Subcutaneous Injection Alone</title>
          <description>lidocaine: 1% lidocaine subcutaneous injection alone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="244"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John P. Kress, MD</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-702-1000</phone>
      <email>jkress@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

